ABSTRACT
Background Cervical cancer is a major public health problem in India, where access to prevention programmes is low. The World Health Organization-Strategic Advisory Group of Experts recently updated their recommendation for human papillomavirus (HPV) vaccination to include a single-dose option in addition to the two-dose option, which could make HPV vaccination programmes easier to implement and more affordable.
Methods We combined projections from a type-specific HPV transmission model and a cancer progression model to assess the health and economic effects of HPV vaccination at national and state-level in India. The models used national and state-specific Indian demographic, epidemiological and cost data, and single-dose vaccine efficacy and immunogenicity data from the IARC India vaccine trial with 10-year follow-up. We compared single- and two-dose HPV vaccination for a range of plausible scenarios regarding single-dose vaccine protection, coverage and catch-up.
Results Under the base-case scenario of life-long protection of single-dose vaccination in 10-year-old girls with 90% coverage, the incremental cost-effectiveness ratio (ICER) of nationwide vaccination relative to no vaccination was $405 per DALY averted and lay below an opportunity-cost based threshold of 30% Indian GDP per capita in each state (state-specific ICER range: $67 to $593 per DALY averted). The ICER of two-dose vaccination versus no vaccination and versus single-dose vaccination was $1403 and minimum $2279 per DALY averted, respectively.
Conclusions Nationwide introduction of single-dose HPV vaccination in India is highly likely to be cost-effective whereas extending the number of doses from one to two would have a less favourable profile.
Funding Bill & Melinda Gates Foundation.
What is already known in this topic In 2020, the World Health Organization (WHO) launched a global call for elimination of cervical cancer as a public health problem, of which HPV vaccination is a key pillar. However, access to HPV vaccination in India is still very low.
In April 2022, the WHO Strategic Advisory Group of Experts (SAGE) issued a recommendation for countries to update their dosing schedules to include a single-dose option. Single-dose HPV vaccination is likely to be more affordable and would greatly facilitate the implementation of HPV vaccination.
The key questions for India are whether, with a realistic cost-effectiveness threshold (30% GDP per capita), single-dose HPV vaccination would be a cost-effective intervention; and whether two-dose vaccination could still be affordable and worthwhile compared to a single-dose schedule, given the uncertainty in its initial efficacy and long-term protection.
What this study adds We used state-specific cancer incidence and locally collected cost data and built plausible vaccination efficacy scenarios based on the IARC India trial to inform the cost-effectiveness estimates.
Single-dose vaccination in India would be cost-effective under a cost-effectiveness threshold of 30% of the Indian GDP per capita and the annual budget impact would be less than 10% of the cost of the current Indian universal childhood vaccination programme.
Even though there was substantial heterogeneity, we confirmed that single-dose vaccination would be cost-effective across all Indian states.
Catch-up single-dose vaccination to age 15 or 20 is a cost-effective strategy. However, the decision to implement catch-up will depend on the willingness of the health authorities to support a higher initial investment. We found two-dose vaccination to have a less favourable cost-effectiveness profile.
How this study might affect research practice and policy Single-dose vaccination achieved a better balance between health benefits and financial burden than two-dose vaccination, even after taking into account uncertainty in the level of protection provided by single-dose HPV vaccination.
Our results could be used by Indian health authorities at the national and state-level to inform their decision and planning of the implementation of HPV vaccination in India and could convey several lessons for other low and middle income countries.
Competing Interest Statement
JB has received support to his institution from the International Agency for Research on Cancer (IARC/WHO) outside the submitted work. All other authors have no conflicts of interests to declare.
Funding Statement
This study was funded by the Bill & Melinda Gates Foundation (grant numbers: OPP48979; INV-039876).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵§ Authors share co-senior authorship
Data Availability
External researchers can make written requests to the IARC for sharing of data regarding the IARC India vaccine trial. Requests will be assessed on a case-by-case basis in consultation with lead and co-investigators. A brief analysis plan and data request will be required and reviewed by the investigators for approval of data sharing. When requests are approved, anonymized data will be sent electronically in password protected files. All data sharing will abide by rules and policies defined by the involved parties. Data sharing mechanisms will ensure that the rights and privacy of individuals participating in research will be protected at all times. Data from public sources are listed in the appendix (pp 7-16). The model code is available from the authors on request.